- Home
- SITC vs PHAR Comparison
SITC vs PHAR Comparison
Compare SITC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- PHAR
- Stock Information
- Founded
- SITC 1965
- PHAR 1988
- Country
- SITC United States
- PHAR Netherlands
- Employees
- SITC N/A
- PHAR N/A
- Industry
- SITC Real Estate Investment Trusts
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- PHAR Health Care
- Exchange
- SITC Nasdaq
- PHAR Nasdaq
- Market Cap
- SITC 603.6M
- PHAR 718.1M
- IPO Year
- SITC 1993
- PHAR N/A
- Fundamental
- Price
- SITC $12.50
- PHAR $10.45
- Analyst Decision
- SITC Hold
- PHAR Strong Buy
- Analyst Count
- SITC 8
- PHAR 3
- Target Price
- SITC $35.25
- PHAR $30.00
- AVG Volume (30 Days)
- SITC 840.9K
- PHAR 2.6K
- Earning Date
- SITC 07-29-2025
- PHAR 07-31-2025
- Dividend Yield
- SITC N/A
- PHAR N/A
- EPS Growth
- SITC 151.17
- PHAR N/A
- EPS
- SITC 10.32
- PHAR N/A
- Revenue
- SITC $227,525,000.00
- PHAR $320,708,000.00
- Revenue This Year
- SITC N/A
- PHAR $13.31
- Revenue Next Year
- SITC $12.69
- PHAR $7.68
- P/E Ratio
- SITC $1.19
- PHAR N/A
- Revenue Growth
- SITC N/A
- PHAR 24.13
- 52 Week Low
- SITC $10.46
- PHAR $6.65
- 52 Week High
- SITC $18.15
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- SITC 60.04
- PHAR 47.51
- Support Level
- SITC $11.30
- PHAR $10.41
- Resistance Level
- SITC $12.32
- PHAR $11.50
- Average True Range (ATR)
- SITC 0.27
- PHAR 0.32
- MACD
- SITC 0.05
- PHAR -0.17
- Stochastic Oscillator
- SITC 91.25
- PHAR 2.26
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.